Iobenguane I-131 (therapeutic)
Azedra was a radioactive drug that homed in on adrenal-type tumours (phaeochromocytoma and paraganglioma) that could not be removed and delivered radiation from inside. It was approved in 2018 and discontinued by its maker in 2024.
Overview
High-specific-activity iobenguane I-131 (Azedra) was approved by the FDA in July 2018 for adults and children aged 12 and over with iobenguane scan-positive, unresectable, locally advanced or metastatic phaeochromocytoma or paraganglioma requiring systemic therapy, on a single-arm phase 2 study in which a quarter of patients halved their antihypertensive medication for at least six months and most had tumour control. It was the first approved therapy for these tumours. Progenics (later Lantheus) discontinued manufacture in 2024, so patients rely on compounded low-specific-activity 131I-MIBG or lutetium-177 dotatate. Myelosuppression, secondary MDS and leukaemia, hypothyroidism and renal toxicity were the main risks; the diagnostic-dose iobenguane (AdreView) is an imaging agent covered separately.
PubChem holds the molecule with stable iodine; the products carry I-123 or I-131 at the same position.
Noradrenaline analogue taken up by the noradrenaline transporter into chromaffin and neuroendocrine tumour cells; iodine-131 beta emission delivers targeted radiation.
- PSMA / SSTR-positive cell
1.Iobenguane I-131 (therapeutic) binds its target on the cancer cell or is taken up by it.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2018 | Iobenguane scan-positive unresectable, locally advanced or metastatic phaeochromocytoma or paraganglioma in patients 12 and older (discontinued 2024) |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Notes
top- Phaeochromocytoma and paraganglioma have no cancer record yet; linked to neuroendocrine tumours.
Latest papers
topQuery for this drug: (TITLE:"Iobenguane I-131" OR ABSTRACT:"Iobenguane I-131" OR TITLE:"therapeutic" OR ABSTRACT:"therapeutic" OR TITLE:"Azedra" OR ABSTRACT:"Azedra" OR TITLE:"131I-MIBG" OR ABSTRACT:"131I-MIBG" OR TITLE:"Ultratrace iobenguane" OR ABSTRACT:"Ultratrace iobenguane") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Iobenguane I-131 (therapeutic), not a curated reading list.
Similar pages
not linked directly; found by shared links- Agent131I-MIBG (iobenguane I-131) therapy
Shares Iobenguane I-123 (cardiac use), Iobenguane I-123, Norepinephrine transporter (NET), MIBG imaging and 131I-MIBG therapy.
- IndicationMetastatic pheochromocytoma and paraganglioma
Shares Iobenguane I-123, Norepinephrine transporter (NET), MIBG imaging and 131I-MIBG therapy, Iodine-123.
- CompanyPDRadiopharma
Shares Iobenguane I-123 (cardiac use), Iodine-123, Iodine-131, Lutetium-177 dotatate.
- IndicationPheochromocytoma and paraganglioma (PPGL)
Shares Iobenguane I-123, Norepinephrine transporter (NET), MIBG imaging and 131I-MIBG therapy, Iodine-123.
- Idea18F-MFBG PET replacing 123I-MIBG scintigraphy
Shares Norepinephrine transporter (NET), MIBG imaging and 131I-MIBG therapy, Iodine-123.
- PersonSimron Singh
Shares Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters), Lutetium-177.
- PersonEmily K. Bergsland
Shares Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters), Lutetium-177.
- IndicationNeuroblastoma (paediatric)
Shares Iobenguane I-123, Norepinephrine transporter (NET), MIBG imaging and 131I-MIBG therapy, Iodine-123.